文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial.

作者信息

Presley Carolyn J, Mohamed Mostafa R, Culakova Eva, Flannery Marie, Vibhakar Pooja H, Hoyd Rebecca, Amini Arya, VanderWalde Noam, Wong Melisa L, Tsubata Yukari, Spakowicz Daniel J, Mohile Supriya G

机构信息

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, United States.

Department of Medicine, University of Rochester Medical Center, Rochester, NY, United States.

出版信息

Front Oncol. 2022 Mar 31;12:835582. doi: 10.3389/fonc.2022.835582. eCollection 2022.


DOI:10.3389/fonc.2022.835582
PMID:35433441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9008713/
Abstract

INTRODUCTION: More older adults die from lung cancer worldwide than breast, prostate, and colorectal cancers combined. Current lung cancer treatments may prolong life, but can also cause considerable treatment-related toxicity. OBJECTIVE: This study is a secondary analysis of a cluster-randomized clinical trial which evaluated whether providing a geriatric assessment (GA) summary and GA-guided management recommendations can improve grade 3-5 toxicity among older adults with advanced lung cancer. METHODS: We analyzed participants aged ≥70 years(y) with stage III & IV (advanced) lung cancer and ≥1 GA domain impairment starting a new cancer treatment with high-risk of toxicity within the National Cancer Institute's Community Oncology Research Program. Community practices were randomized to the intervention arm (oncologists received GA summary & recommendations) versus usual care (UC: no summary or recommendations given). The primary outcome was grade 3-5 toxicity through 3 months post-treatment initiation. Secondary outcomes included 6-month (mo) and 1-year overall survival (OS), treatment modifications, and unplanned hospitalizations. Outcomes were analyzed using generalized linear mixed and Cox proportional hazards models with practice site as a random effect. NCT02054741. RESULTS & CONCLUSION: Among 180 participants with advanced lung cancer, the mean age was 76.3y (SD 5.1), 39.4% were female and 82.2% had stage IV disease. The proportion of patients who experienced grade 3-5 toxicity was significantly lower in the intervention arm vs UC (53.1% vs 71.6%, P=0.01). More participants in the intervention arm received lower intensity treatment at cycle 1 (56.3% vs 35.3%; P<0.01). Even with a cycle 1 dose reduction, OS at 6mo and 1 year was not significantly different (adjusted hazard ratio [HR] intervention vs. UC: 6mo HR=0.90, 95% CI: 0.52-1.57, P=0.72; 1 year HR=0.89, 95% CI: 0.58-1.36, P=0.57). Frequent toxicity checks, providing education and counseling materials, and initiating direct communication with the patient's primary care physician were among the most common GA-guided management recommendations. Providing a GA summary and management recommendations can significantly improve tolerability of cancer treatment among older adults with advanced lung cancer.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e8/9008713/fd794d4f1c00/fonc-12-835582-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e8/9008713/5238d6f54e55/fonc-12-835582-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e8/9008713/967275cb7fb9/fonc-12-835582-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e8/9008713/fd794d4f1c00/fonc-12-835582-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e8/9008713/5238d6f54e55/fonc-12-835582-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e8/9008713/967275cb7fb9/fonc-12-835582-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4e8/9008713/fd794d4f1c00/fonc-12-835582-g003.jpg

相似文献

[1]
A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial.

Front Oncol. 2022-3-31

[2]
Association of Oncologist-Patient Communication With Functional Status and Physical Performance in Older Adults: A Secondary Analysis of a Cluster Randomized Clinical Trial.

JAMA Netw Open. 2022-3-1

[3]
Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program.

JAMA Oncol. 2020-2-1

[4]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[5]
Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.

J Clin Oncol. 2023-2-1

[6]
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.

Lancet. 2021-11-20

[7]
Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial.

JAMA Oncol. 2021-11-1

[8]
Patient- vs Physician-Initiated Response to Symptom Monitoring and Health-Related Quality of Life: The SYMPRO-Lung Cluster Randomized Trial.

JAMA Netw Open. 2024-8-1

[9]
Primary Treatment Modification and Treatment Tolerability Among Older Chemotherapy Recipients With Advanced Cancer.

JAMA Netw Open. 2024-2-5

[10]
Communication About Fall Risk in Community Oncology Practice: The Role of Geriatric Assessment.

JCO Oncol Pract. 2022-10

引用本文的文献

[1]
Intracluster correlation coefficients from cluster randomized trials conducted within the NCI Community Oncology Research Program (NCORP).

J Natl Cancer Inst Monogr. 2025-3-1

[2]
Management of lung cancer in older adults.

Z Gerontol Geriatr. 2025-3

[3]
Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.

J Thorac Dis. 2024-9-30

[4]
Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes.

J Natl Cancer Inst. 2024-11-1

[5]
Geriatric Oncology as an Unmet Workforce Training Need in the United Kingdom-A Narrative Review by the British Oncology Network for Undergraduate Societies (BONUS) and the International Society of Geriatric Oncology (SIOG) UK Country Group.

Cancers (Basel). 2023-9-28

[6]
Frailty assessment to individualize treatment in older patients with lymphoma.

Eur Geriatr Med. 2023-12

[7]
Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy.

JAMA Oncol. 2023-3-1

本文引用的文献

[1]
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.

Lancet. 2021-11-20

[2]
Prevalence of and factors associated with treatment modification at first cycle in older adults with advanced cancer receiving palliative treatment.

J Geriatr Oncol. 2021-11

[3]
Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage study.

J Geriatr Oncol. 2021-7

[4]
Immunotherapy in Older Adults With Cancer.

J Clin Oncol. 2021-7-1

[5]
Functional Disability Among Older Versus Younger Adults With Advanced Non-Small-Cell Lung Cancer.

JCO Oncol Pract. 2021-6

[6]
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

J Natl Compr Canc Netw. 2021-3-2

[7]
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study.

ESMO Open. 2021-2

[8]
Cancer Statistics, 2021.

CA Cancer J Clin. 2021-1

[9]
Octogenarians treated for thoracic and lung cancers: Impact of comprehensive geriatric assessment.

J Geriatr Oncol. 2021-4

[10]
Older adult participation in cancer clinical trials: A systematic review of barriers and interventions.

CA Cancer J Clin. 2021-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索